Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
First-In-Class But Low Revenues
Executive Summary
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.
China May Ease Data Transfer Rules But Regulatory Ambiguity Remains
China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.
Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.